The importance of lipid solubility and receptor selectivity of β-adrenoceptor blocking drugs for the occurrence of symptoms and side-effects in out-patients
Authors:
- 1 July 1989
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 226 (1) , 17-23
Abstract
Theodorsen L, Brørs O (Department of Pharmacotherapeutics. University of Oslo, Oslo, Norway). The importance of lipid solubility and receptor selectivity of β-adrenoceptor blocking drugs for the occurrence of symptoms and side-effects in out-patients. Short-term studies indicate that the side-effects of adrenergic β-receptor blockade may be influenced by lipid solubility and receptor selectivity of the blockers. The aim of the present study was to investigate the extent to which lipid solubility and receptor selectivity are related to the occurrence of symptoms during ordinary β-blocker treatment in out-patients. Two hundred and five patients (mean age 60 years) on β-blockade were interviewed about their symptoms. Eighty-five per cent of the patients had been on β-blocker treatment for more than 1 year. The blockers most commonly used were atenolol (51.0%). timolol (20.0%). propranolol (18.5%) and metoprolol (7.8%). β-Blocker treatment was associated with a significantly increased frequency of central nervous system and peripheral symptoms. The increase in central nervous system symptoms was significantly smaller in those on β-blockers with low rather than with intermediate (P = 0.015) or high lipid solubility (P = 0.007). The increase in peripheral symptoms was not significantly different with β1-selective and non-selective blockers. The results indicate that the liability of β-blockers to cause side-effects on the central nervous system is determined partly by their lipid solubility, and that receptor selectivity has only a small impact on their tendency to cause peripheral side-effects.Keywords
This publication has 19 references indexed in Scilit:
- Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties.Circulation, 1987
- Atenolol versus pindolol: Side-effects in hypertensionEuropean Journal of Clinical Pharmacology, 1985
- Central nervous system side-effects with hydrophilic and lipophilic ?-BlockersEuropean Journal of Clinical Pharmacology, 1985
- CNS-related side-effects with metoprolol and atenololEuropean Journal of Clinical Pharmacology, 1985
- CNS-related (side-)effects of ?-Blockers with special reference to mechanisms of actionEuropean Journal of Clinical Pharmacology, 1985
- Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in manJournal of Pharmacokinetics and Biopharmaceutics, 1984
- Beta-adrenoceptor blocking drugs: Adverse reactions and drug interactionsPharmacology & Therapeutics, 1983
- Comparison of beta‐adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol).British Journal of Clinical Pharmacology, 1982
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- Direct evidence for an interaction of β-adrenergic blockers with the 5-HT receptorNature, 1977